Article
Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Human pathology - 1 Nov 2014
Fisher Kevin E, Cohen Cynthia, Siddiqui Momin T, Palma John F, Lipford Edward H, Longshore John W
Abstract excerpt
Malignant melanoma patients require BRAF mutation testing prior to initiating BRAF inhibitor therapy. Molecular testing remains the diagnostic gold standard, but recent work suggests that BRAF immunohistochemistry (IHC) confers comparable results. Sample attributes and scoring criteria that may affect BRAF IHC interpretation, however, are poorly defined. We investigated formalin-fixed, paraffin-embedded samples...
Topics
- DNA Mutational Analysis
- Humans
- Immunohistochemistry
- Melanoma
- Mutation
- Proto-Oncogene Proteins B-raf
- Reproducibility of Results
- Skin Neoplasms